Insider Transactions Report

Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, Inc., acquired 180,095 shares of Common Stock in a direct transaction on May 18, 2026. Following this transaction, he owns 2,259,046 shares. Kristina Masson, EVP of Business Operations, acquired 72,706 shares of Common Stock indirectly on the same date. She now owns 386,343 shares. Both transactions involved restricted stock units (RSUs) with a price of $0.00 per share, vesting over time, subject to continued service. Footnote F2 indicates that the shares held by Peter Blume-Jensen are also beneficially owned by Kristina Masson due to their marital relationship, with her disclaiming beneficial ownership except for her pecuniary interest. Similarly, Footnote F3 states that shares held by Kristina Masson are also beneficially owned by Peter Blume-Jensen, with his disclaimer of beneficial ownership except for his pecuniary interest. The reporting date for these transactions is May 18, 2026, and the signatures were dated May 20, 2026.